E
Epizyme Inc
F:EPE
Epizyme Inc
F:EPE
Price:
559
EUR
3.33%
Market Closed
Market Cap:
€92.2B
Relative Value
There is not enough data to reliably calculate the relative value of EPE.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EPE
Relative Value
Base Case
Not Available
Multiples Across Competitors
EPE Competitors Multiples
Epizyme Inc Competitors
Epizyme Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
404.2B USD | 6.7 | 97.4 | 16 | 22.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.1B USD | 5.4 | 25.7 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
178.6B USD | 6.1 | 21.1 | 13.1 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.8B USD | 9.6 | 29.1 | 21.9 | 22.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.4B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.3B AUD | 3.2 | 35.7 | 11.7 | 14.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.8 | 34.7 | 37.6 | 38.4 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.8B USD | 11.3 | 133.8 | 74.6 | 82.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
